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TELECONFERENCE OF THE 
BOARD OF SCIENTIFIC COUNSELORS, OFFICE OF INFECTIOUS DISEASES 
Centers for Disease Control and Prevention 
March 28, 2016 
2:00–4:00 PM (EDT) 
A 2-hour, open public teleconference of the Board of Scientific Counselors (BSC), Office of Infectious 
Diseases (OID), Centers for Disease Control and Prevention (CDC), was held on March 28, 2016, from 
2:00–4:00 PM (EDT) to provide reports from recent CDC program meetings and to update the Board on 
current emerging infectious disease outbreak responses and on administrative/budget issues.  Phone 
lines were open for BSC/OID members, CDC partners, CDC staff, and members of the public.  A list of 
callers is included at the end of this report. 
Opening Remarks 
BSC/OID Chair Ruth Berkelman, Rollins Professor, Emory University, called the meeting to order and was 
joined in welcoming participants by Rima Khabbaz, CDC Deputy Director for Infectious Diseases, and 
Robin Moseley, the BSC/OID Designated Federal Official.  Participants included a new BSC member, 
Salmaan Keshavjee, Associate Professor of Global Health and Social Medicine, Harvard Medical School, 
and two new BSC/OID liaison representatives:  Deborah Yokoe, Healthcare Infection Control Practices 
Advisory Committee (HICPAC), and Barbara Cole, Advisory Council for the Elimination of Tuberculosis 
(ACET).  Brooke Courtney, Senior Regulatory Counsel in the Office of Counterterrorism and Emerging 
Threats, Office of the Chief Scientist, U.S. Food and Drug Administration (FDA), attended on behalf of 
BSC/OID member Steve Ostroff. 
Report from the CDC Syphilis Summit 
As described in Sexually Transmitted Disease Surveillance 2014, for the first time since 2006, increases 
were reported in the following nationally notifiable sexually transmitted diseases (STDs):  chlamydia, 
gonorrhea, and syphilis and congenital syphilis.  Gail Bolan, Director, Division of STD Prevention, 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), reported that the 
number of cases of syphilis is continuing to rise, especially among men who have sex with men (MSM) 
and among women of reproductive age.  While the 2015 STD surveillance data are still being verified, 
more than 500 cases of congenital syphilis were reported in 2015, which is a 10% increase from 2014, 
and cases of ocular syphilis were reported predominantly among MSM with HIV, with some cases 
leading to blindness.  An Epi-Aid analysis of medical and public health case investigation records in North 
Carolina (a state where rates of syphilis are ranked ninth nationally) identified 20 cases in 2014 and 43 in 
2015.  The ocular syphilis cases were sporadic throughout the state, with no cases among sex partners 
of persons with ocular syphilis (suggesting that ocular syphilis is not likely due to a particular strain of 
syphilis).  Most cases of ocular syphilis (as compared with cases of non-ocular syphilis) were reported 
among older white males with HIV, a group that has above-average access to medical care. 
CDC hosted a Syphilis Summit on January 26–28 to develop recommendations on syphilis control in the 
United States.  The participants suggested that separate syphilis action plans be developed to address 
(1) the rates of syphilis among MSM and (2) the emerging epidemic of congenital syphilis.  It was also 
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suggested that CDC revisit case definitions for congenital syphilis; prioritize and evaluate program 
strategies; identify transmission dynamics; develop resource allocation models and improve policies, 
guidelines, and structural interventions (e.g., screening frequency, new digital technologic approaches, 
electronic health record [EHR] data opportunities, and messaging on condom use); and employ a 
comprehensive sexual health approach for men to diagnose and treat STDs in high-risk MSM 
populations and a sense of public health and health care urgency when a pregnant women is diagnosed 
with syphilis.  A meeting report will be issued in June, and syphilis action plans will be presented at a 
conference in September. 
Mike Loeffelholz, BSC/OID member, attended the Summit and described the laboratory issues 
presented, which included interpretation of reverse algorithm1 testing results; development of 
improved diagnostics for syphilis (e.g., point-of-care tests to support early treatment) and neurosyphilis; 
and the need for guidance on clinical management of serofast patients (patients with unchanged 
serologic test titers after treatment).  BSC/OID member Ruth Lynfield, who also attended the Summit, 
emphasized the need to stem the “alarming” epidemic of congenital syphilis. 
DISCUSSION 
In response to questions, Dr. Bolan noted that 
• PCR testing on the primary lesion can confirm infection before a patient becomes seropositive. 
• Correlations have not been found between rising rates of STDs and use of HIV pre-exposure 
prophylaxis (PrEP) or long-acting contraceptives.  CDC continues to evaluate these and other factors. 
BSC members commented that 
• CDC should continue to work with website owners to provide linkages to STD information (including 
information about testing services) to users of dating-focused social media sites. 
• Addressing the resurgence of congenital syphilis requires improved communications with local 
policy makers to remove barriers to detection and treatment, including working with maternal and 
child health programs.  Lack of access to care and mistrust of authorities may be significant issues in 
some communities. 
• The number of cases of congenital syphilis in 2015 in the United States is unacceptable. 
Report from the External Program Review of the Division of 
HIV/AIDS Prevention (DHAP) 
Jonathan Mermin, Director, NCHHSTP, and Chris Cagle, Associate Director for Policy, Planning, and 
Communications, DHAP, reported on an external program review held on March 2–3 to elicit feedback 
on three innovative approaches to HIV prevention: 
• Providing rapid feedback on HIV surveillance data to health departments and community-based 
organizations that reported the data.  The reviewers were supportive of this feedback on HIV 
                                                          
1 A reverse sequence screening algorithm for syphilis (adopted by many clinical laboratories) begins with a 
treponemal screening assay and then tests screen-positive samples by a non-treponemal test such as the rapid 
plasma reagin (RPR). Samples that are positive by the screening test but negative by RPR are tested by a second, 
confirmatory treponemal assay. 
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prevention efforts.  It was recommended that CDC work with health departments to reduce the 
number of variables used for reporting. 
• The Data to Care approach, which uses surveillance data from HIV-positive individuals (i.e., CD4 
counts and viral loads) to identify persons who are no longer in care and may need to be relinked 
with healthcare services.  The reviewers were supportive of the Data to Care approach, but 
emphasized that improving the HIV care continuum requires addressing not only linkage to care but 
also barriers to staying in care. 
• Using whole-genome sequencing (WGS) to create phylogenetic trees of viruses isolated from persons 
newly diagnosed with HIV that can be used to identify (and then control) clusters of HIV infections.  
The reviewers recommended that CDC conduct pilot studies to confirm that this is an effective way 
to prevent HIV spread. 
The recommendations of the DHAP external review will be finalized and posted in April. 
Efforts by the National Center for Immunization and 
Respiratory Diseases (NCIRD) in the Flint, Michigan, Water 
Crisis Response 
Cynthia Whitney, Chief, Respiratory Diseases Branch, Division of Bacterial Diseases, NCIRD, reported 
that the summer (2014) after the Flint water supply was switched to the Flint River (from Detroit-
supplied Lake Huron), the number of Legionnaires’ disease (LD) cases rose from an average of 8–11 per 
year to more than 40, with the majority of cases associated with a single hospital.  The Genesee County 
Health Department contacted CDC in February 2015, but the Michigan Department of Health and 
Human Services decided that a CDC field investigation was not warranted at the time.  Despite 
remediation activities by the affected hospital, a similar increase in cases was reported again the 
following summer.  This time, the hospital hired a private consultant and added a water disinfectant to 
its water system.  Although no additional cases have been reported since October 2015, there is 
continuing concern about what may happen this summer. 
CDC was approached again in January 2016, as part of the larger response to the lead contamination of 
the Flint water system.  CDC was asked to help identify buildings that require water management 
programs (e.g., hospitals, buildings that house elderly persons, and tall buildings with complex water 
systems).  As part of this effort, CDC developed an LD toolkit to help building managers implement water 
management programs based on the American Society of Heating, Refrigerating and Air-Conditioning 
Engineers (ASHRAE) Standard 188-2015 (see also pages 10–13 of the minutes of the December 2015 
BSC/OID meeting).  Version 1.0 of the toolkit will be distributed in Genesee County this week by the 
Michigan health department.  CDC is also working with the Michigan and Genesee County health 
departments to increase testing for LD and to encourage the isolation of bacterial isolates (from 
sputum) for use in the investigation. 
Although the water supply has been switched back to the Detroit water source, the presence of 
abandoned buildings with stagnant water in their pipes may facilitate further growth of LD or other 
infectious agents; in addition, frequent water main breaks that introduce dirt into the water system can 
deplete the chlorine.  Lower rates of chlorine may also be caused by higher temperatures during the 
summer months.  The U.S. Environmental Protection Agency has expanded water testing (which can 
help localities adjust chlorine levels) from 10 to 34 sites. 
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CDC is also helping with public health communications, in coordination with state and county health 
departments, and taking into account other sources of information, including a Wayne State University 
communications group hired by the governor and a Virginia Tech laboratory group that is conducting 
independent water testing.  CDC has developed LD fact sheets for the general public and for healthcare 
providers, and has answered questions from the Genesee County Medical Society. 
Since the most recent BSC meeting (December 2015), NCIRD and the National Center for Environmental 
Health, CDC, have received funding to evaluate two LD prevention efforts:  1) cooling-tower registration 
and monitoring, as piloted by New York City, and 2) enhanced water testing at hospitals, as specified in 
Veterans Health Administration (VHA) Directive 1061.2  CDC is also strengthening the Environmental 
Legionella Isolation Techniques Evaluation (ELITE) Program, which certifies laboratories that perform 
environmental testing for Legionella; evaluating the use of PCR during LD investigations; and (as a long-
term-project) developing rapid methods for monitoring water systems for Legionella.  In addition, CDC is 
developing a Vital Signs report on Legionella prevention scheduled for June 6.  The Vital Signs report will 
include a fact sheet that aims to engage clinicians and building managers in LD prevention, and an 
MMWR article that evaluates lessons learned from field investigations of LD outbreaks between 2000 
and 2014. 
DISCUSSION 
In response to questions, Dr. Whitney noted that 
• The LD toolkit will be disseminated as a pilot stage to the Michigan Department of Health and 
Human Services for feedback, and a more final version will be posted in June, along with the Vital 
Signs materials. 
• CDC is in talks with the Association of Public Health Laboratories and the Wisconsin State Laboratory 
of Hygiene about expanding the ELITE Program to make it accessible to a larger number of public 
health and commercial laboratories. 
• It is important to work with all levels of government—county, state, and federal—to advance the 
public health response in Flint. 
Dr. Berkelman noted that a national workshop on legionellosis sponsored by the Sloan Foundation will 
be held in May at Emory University. 
CDC’s Response to the Zika Virus Disease Outbreak 
Tracee Treadwell, Associate Director for Infectious Disease Preparedness, National Center for Emerging 
and Zoonotic Infectious Diseases (NCEZID), and former Deputy Incident Manager for the Zika response, 
reported that, as of March 18, 264 travel-related cases of Zika virus disease have been reported in the 
continental United States and Hawaii, including 19 in pregnant woman.  For mosquito-borne 
transmissions, 249 have been reported in Puerto Rico, 14 in American Samoa, and 11 in the U.S. Virgin 
Islands. 
Two diagnostic tests are FDA-approved under Emergency Use Authorizations:  the Zika MAC-ELISA, 
which tests for a history of infection, and the Trioplex rRT-PCR, which tests for active infection.  Thirteen 
                                                          
2 Department of Veterans Affairs.  Prevention of healthcare-associated Legionella disease and scald injury from 
potable water distribution systems.  VHA Directive 1061; 2014. 
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laboratories are accredited to use the MAC-ELISA, and 26 more are working towards accreditation.  The 
Trioplex rRT-PCR has been distributed to 77 laboratories that are working towards accreditation. 
DISCUSSION 
In response to questions, Dr. Treadwell noted that 
• The ability of the MAC-ELISA to distinguish Zika from dengue depends on the seropositivity of the 
sample.  A definitive diagnosis requires a third test, the plaque-reduction neutralization test (PRNT), 
which is labor intensive to conduct and may not be a reliable test for congenital infection.  BARDA 
(the Biomedical Advanced Research and Development Authority) is considering how to facilitate the 
development of faster and more sensitive tests, and CDC is continuing to receive requests from test 
manufacturers for help in validating new tests.  (Additional information on this point will be 
provided to the BSC/OID.)  Courtney Brooke, FDA, added that FDA is working with several clinical 
laboratories to evaluate Zika tests developed for in-house use. 
• CDC is prioritizing testing of pregnant women—and women who might be pregnant—who have 
traveled in Zika-infected areas.  For now, a lesser priority is to test male travelers, who are advised 
to refrain from sexual activity for a period of time after their return.  CDC has begun a study of the 
persistence of the Zika virus in bodily fluids, including semen. 
• The turnaround time to receive test results when a physician orders a Zika test depends in part on 
whether the physician’s state laboratory is able to do the testing and whether the laboratory has a 
backlog. 
• CDC has issued 9 travel notices about Zika, as well as 15 MMWRs that provide interim guidance on 
Zika surveillance, prevention, and treatment.  A Zika Action Plan Summit is planned for April 1 to 
bring together representatives from many U.S. states and territories, including Puerto Rico.  It is 
hoped that the Summit will reinvigorate local efforts to address mosquito-borne threats, by 
providing opportunities to share best practices for vector control and mosquito field-testing.  
Information will be provided to the BSC/OID on whether a national contract to improve vector 
control is under consideration. 
• Ongoing surveillance efforts include studies of microcephaly and Guillain-Barré syndrome in Brazil 
and a case-control study in Colombia that follows a cohort of women infected during the first or 
second trimester of pregnancy.  The results of these studies will inform guidance updates.  
Information on Zika and microcephaly in Brazil, Colombia, and other countries is available on the 
Pan American Health Organization (PAHO) website.  CDC continues to coordinate closely with PAHO 
and the World Health Organization on strategic plans for responding to Zika. 
Also during the discussion, BSC members from state health departments expressed concerns about 
preparedness funding.  CDC is continuing to pursue supplemental resources to support the US response 
to Zika.  In the meantime, CDC has had to use existing resources to support the agency’s most critical 
needs.  These efforts have included redirecting other preparedness funding from state grants and the 
Strategic National Stockpile, as well as using other balances previously available for other activities, to 
increase on-going response activities.  BSC members raised concerns about potential effects of these 
redirections.  CDC recognizes that these resources are critical to support short-term activities while the 
agency continues to work with the Congress to fund CDC’s Zika efforts and replenish resources directed 
from other sources. 
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Update on CDC’s Infectious Disease Budget 
Rima Khabbaz reported that the fiscal year (FY) 2016 budget—which passed as part of an omnibus 
funding measure in December 2015—provides $7.178 billion, which includes CDC Budget Authority of 
$6.27 billion (an increase of $273 million from FY 2015); $892 million in Prevention and Public Health 
Fund (an increase of $5 million); and $15 million in the Public Health and Social Services Emergency 
Fund (the same as in FY 2015).  The FY 2016 budget includes funding for the Antibiotic Resistance (AR) 
Solutions Initiative and for prescription drug overdose prevention.  It also includes a provision that 
prohibits purchase of needles but allows support for other elements needed to implement syringe 
services programs in communities determined to be at risk for significant increases in hepatitis 
infections or an HIV outbreak due to injection drug use. 
The FY 2016 budget includes level funding overall for Immunization and Respiratory Diseases (including 
$8 million to support billing by health departments for immunization services); increased funding for 
HIV, Viral Hepatitis, STD, and TB Prevention (increases of $2 million for school health and $2.67 million 
for viral hepatitis); and increased funding for Emerging and Zoonotic Infectious Diseases ($160 million 
for the AR Solutions Initiative; an increase of $4 million for food safety; an increase of $3 million for the 
National Healthcare Safety Network; and $8 million [new] for laboratory safety and quality, with an 
additional $5 million for laboratory safety and training in the Public Health Scientific Services budget 
line). 
The FY 2017 President’s Budget Request includes $7 billion for CDC, which is a decrease of $164,199 
from FY 2016.  The request includes 
• Four agency initiatives:  Combating Antibiotic-Resistant Bacteria, Good Health and Wellness in 
Indian Country, Prescription Drug Overdose, and mental health/evaluation of suicide prevention 
programs 
• Increases for the Vaccines for Children Program, for viral hepatitis prevention, for the antimicrobial 
resistance and Advanced Molecular Detection (AMD) initiatives, for quarantine and migration to 
support refugee resettlement, and for laboratory science and safety enhancement 
• Additional funding for global public health capacity-building activities, including the Global Health 
Security Agenda (GHSA), and for polio eradication 
• Elimination of funding for chronic fatigue syndrome 
DISCUSSION 
In response to questions, Dr. Khabbaz noted that 
• The budget request for NCIRD includes a reduction in support for immunization services, which 
reflects an expectation of increased financial coverage through expanded health insurance.  This 
reduction was also proposed in previous years. 
• Responses to outbreaks of Legionnaires’ disease and other non-vaccine-preventable respiratory 
diseases are supported in the emerging infections budget line. 
BSC members commented that a major underlying, ongoing challenge is to build public health capacity 
to address infectious threats as they emerge.  When CDC focuses on a serious issue such as Ebola or 
Zika, it is important that other public health issues are not neglected. 
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Priorities for CDC’s Antibiotic Resistance Solutions Initiative 
Michael Craig, Senior Adviser for AR Coordination and Strategy, Division of Healthcare Quality 
Promotion, NCEZID, noted that the CDC report Antibiotic Resistance Threats in the United States, 2013 
was the impetus for the National Action Plan for Countering Antibiotic-Resistant Bacteria (CARB). 
The CDC AR Initiative will support implementation of CDC’s component of the CARB plan, which specifies 
goals, activities, and targets for U.S. Government agencies.  The largest portion of extramural funding 
will be distributed to the 50 states and to 6 large cities, via the Epidemiology and Laboratory Capacity for 
Infectious Diseases (ELC) program, to improve AR detection and outbreak response in healthcare 
settings.  Up to 25 jurisdictions will also receive support to build sustainable, comprehensive programs 
for AR prevention. 
ELC support will also help states address drug-resistant gonorrhea and drug-resistant foodborne 
diseases.  The AMD initiative has already improved state-level capacity to conduct WGS of drug-resistant 
Salmonella, building on the Listeria project, which validated the use of AMD techniques for outbreak 
detection. 
In addition, the AR Initiative will support antibiotic stewardship programs, educational activities, and 
improved laboratory-based detection of carbapenem-resistant Enterobacteriaceae (CRE) and 
carbapenem-resistant pseudomonas.  CDC will also establish an AR laboratory network of 7–8 state-
based laboratories that serve as regional reference laboratories and conduct high-level research on 
resistant pathogens.  Additional information is available in an overview of the AR Solutions Initiative. 
DISCUSSION 
In response to questions, Mr. Craig noted that 
• CDC efforts to address drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB) include 
international activities to improve TB treatment and refugee health, as well as a clinical trial to 
evaluate the use of videoconferencing to implement DOTS (directly observed treatment, short 
course) therapy.  CDC has also established a stockpile of TB drugs to address domestic shortages, as 
specified in the National Action Plan for Combating Multidrug-Resistant Tuberculosis, which was 
developed as a follow-up to CARB. 
• CDC is evaluating the use of WGS to investigate CRE outbreaks in hospitals.  The goal is to use WGS 
to identify resistance patterns in healthcare-associated infection outbreaks, as is currently done 
during outbreaks of some enteric pathogens.  Other aims include improving antibiotic stewardship 
and extending the Get Smart campaign to outpatient settings. 
• CDC efforts to advance international efforts to combat AR (the last of the five CARB goals) include 
expanding the laboratory-based surveillance component of the GHSA Antimicrobial Resistance 
Action Package to non-GHSA countries. 
Phone Lines Open to Partners and the Public 
Guillermo Ruiz-Palacios, BSC/OID liaison representative from the National Institutes of Health and 
Tertiary Referral Hospitals, Mexico City, reported that an increase in the number of cases of Guillain-
Barré syndrome in southern Mexico may be associated with the ongoing outbreak of Zika virus disease.  
His organization may contact CDC to request assistance with diagnosis and serologic testing. 
8 
 
In response to a question from a Board member about an outbreak of bacterial infections in Wisconsin 
caused by Elizabethkingia anophelis, Dr. Khabbaz reported that the source and route of transmission of 
the bacteria are still under investigation. 
Proposed July BSC/OID Meeting 
An in-person BSC/OID meeting may be held on July 27 and 28 or later in the summer or in early fall to 
continue discussion of the issues raised today, as well as other topics previously suggested by Board 
members (e.g., prevention and control of mosquito-borne and tickborne diseases).  This proposal will be 
followed up by e-mail. 
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*Callers also included individuals from OID partner organizations and members of the public. 
I hereby certify that to the best of my knowledge, the foregoing minutes of the proceedings of the 
meeting of the Board of Scientific Counselors, Office of Infectious Diseases, on March 28, 2016, are 
accurate and complete. 
   /S/ 
Ruth Berkelman, M.D. 
Chair, BSC, OID 
05/31/16 
Date
